ChemPath: Brief Lipid Update Flashcards

1
Q

What is the optimal medical therapy for people with coronary heart disease?

A
  • Intensive lifestyle modification
  • Aspirin
  • High-dose statin (atorvastatin 40-80mg OD)
  • Optimal blood glucose control
  • Thiazides
  • Assessment for probable T2DM

key message = aggressive management of blood pressure and lipids improves survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the statistical mortality benefit of adding a thiazide diuretic to outstanding BP medications, following an MI?

A

Worth it, as 2 in 100 will be prevented from a further MI in the next 5 years

Shown by the SPRINT Study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List some options for people with statin intolerance.

A
  • Ezetemibe (reduced absorpotion)
  • Plasma exchange
  • PCSK9 inhibitors

NOTE: niacin is no longer available

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the function of PCSK9 and PCSK9 inhibitor

A
  • PCSK9 targets the LDL receptor (LDLR) leading to its endocytosis and their degradation
  • This reduces the ability of the liver to take up cholesterol from the blood
  • Threfore a PCSK9 inhibitor prevents the action of PCSK9, resultin in increased levels of LDLRs which uptake LDLs and reduce its serum level.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Name a PCSK9 inhibitor.

A

Evolocumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which patient group may benefit from PCSK9 inhibitors?

A

Patients who are at very high risk (e.g. familial hypercholesterolaemia)

Statin-intolerant patients

NOTE: PCSK9 inhibitors reduce the incidence of cardiovascular events but has NO effect on mortality, and has a high Number Needed to Treat (NNT) (Fourier study)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How long does it take to see benefit from good glucose control?

A

15 years of good glucose control in newly diagnosed T2DM before you see a reduction in complications

Shown by the UKPDS study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the legacy effect?

A

A period of good glycaemic control will have a beneficial effect on mortality for up to 10 years even if the patient reverts to poor glycaemic control after a certain period of time.

Shown by the UKPDS study

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What did the DCCT study show?

A

Good control in type 1 diabetes improves outcomes

*Legacy effect was shown here too like the UKPDS study. but the UKPDS focussed on T2DM, the DCCT focused on T1DM*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What did the Advance study show?

A

Targeting HbA1c of less than 6.5% reduces microvascular events

Intensive glucose control was associated with an increased risk of severe hypoglycaemia and hospitalisation BUT no increased risk of mortality (unlike Accord study)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the effects of sudden aggressive blood glucose control in patients with long-standing poor glycemic control and cardiovascular complications?

A
  • Reduced the incidence of complications
  • Increased mortality (likely due to precipitating tachycardia and arrhythmias)

Really important to consider whether the patient has atheromas to begin with before suddenly tightening glucose control

This was found by the ACCORD trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Describe how SGLT2 inhibitors can reduce blood glucose.

A

Increases urinary excretion of glucose by inhibiting re-uptake –> causes a reduction in blood glucose and blood pressure. It also helps loose weight!

NOTE: this can also be used in heart failure because of its diuretic effect

Main side-effects: UTIs due to glycosuria, rarely DKA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Name an SGLT2 inhibitor

A

Empagliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What were the key findings of the EMPA-REG study?

A

Significant reduction in mortality after just 4 years of using Empagliflozin.

Reduces HbA1c

Treats heart failure due to diuresis

Prevents nephropathy as it reduces albuminuria by letting glucose pass into the tubules instead - protects the kidneys (initial sharp reduction in GFR but then recovers)

*Albumin is poisonous to the kidneys so these SGLT2 inhibitors are renal-protective*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What side-effect finding in the CANVAS study was then not seen in the EMPA-REG, OBSERVE-4D and DECLARE study

A

CANVAS study found that the use of canagliflozin (an SGLT2 inhibitor) increased amputation risk.

OBSERVE-4D did not see any evidence for excess amputations with canagliflozin.

DECLARE did not see it either with Dapagliflozin (in fact it saw that Dapagliflozin reduced CVD death and hospitalisation for heart failure)

**EMPA-REG **did not see any increased risk of amputations with empagliflozin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the physiological role of GLP1?

A
  • Produced by the gut and signals to the pancreas to produce more insulin (incretin effect = oral glucose stimulates higher insulin secretory response compared to serum glucose)
  • Also has a direct effect on satiety and gastric emptying
17
Q

List three examples of GLP1 analogues.

A
  • Exanatide (synthetic version of exendin 4) –> incresed hypothalamic satiety
  • Liraglutide (saxenda) –> shown to reduce significant CVD and MI events just after 4 years
  • Semaglutide (ozempic) –> weight loss and improves CVD outcomes

All injections at the moment so SGLT2 inhibitors are preferred in combination with metformin

18
Q

What breaks down GLP1?

A

DPP4

19
Q

Which class of drugs inhibits the breakdown of GLP1?

A

Gliptins (by inhibiting DPP4 and, thereby, preventing the breakdown of GLP1)

Likely to be phased out as GLP-1 analogues work better

20
Q

Principles of managing hyperglycaemia in T2DM

A

1. Metformin
- if non-insulin monotherapy at maximum tolerated dose does not achieve or maintain the HbA1c target after 3 months add

2. Dual Therapy with Metformin:
- 1) Metformin + Sulphonylureas
- 1) Metformin + Thiazolidinedione
- 1) Metformin + GLP-1 agonist (preferred if obese)
- 2) Metformin + SGLT2 inhibitor (preferred if Heart Failure or CKD)

**3. Triple Thearpy **
- 1) Metformin + Sulphonylureas + Gliptin
- 1) Metformin + Sulphonylureas + Thiazolidinedione
- 1) Metformin + Sulphonylureas/ Thiazolidinedione + SGLT2 inhibitors
- 2) Insulin

4. Metformin + Sulphonylurea + GLP-1analogue

you move forward wiht treatment if

21
Q

What dual therapy in T2DM is preferred for patients that are obsese

A

Metformin + GLP-1 analogue

22
Q

What dual therapy in T2DM is preferred for patients that have HF or CKD

A

Metformin + SGLT2-inhibitor